The BIM (BCL2-Interacting Mediator of cell death, also known as BCL2L11) protein is a BH3-only proapoptotic member of the BCL-2 family that is absolutely required for the cancer killing of such drugs via the intracellular or mitochondrial pathway, elicited via upregulation of its expression at different levels [8–14]. This evidence concerns the gene BCL2L11 and cancer.